Video Library

First-line TAGRISSO: Watch expert discussions and informational videos

TAGRISSO Mechanism of Action Video

Mechanism of Action

See how first-line TAGRISSO works in the body.
7 min.

TAGRISSO CNS Response Panel Discussion Video

Dr West & panel: What to know before choosing a 1L mNSCLC therapy

Dr Jack West from City of Hope Comprehensive Cancer Center in Duarte, California, moderates a panel of expert physicians discussing the role of IO and EGFR TKIs in the first-line treatment of patients with metastatic EGFR mutation-positive NSCLC. They conclude by looking at progression-free survival with TAGRISSO® (osimertinib) vs standard-of-care EGFR TKIs in the FLAURA study.
10 min 42sec.

TAGRISSO clarity on IO and TKI study data in 1L mNSCLC video

Dr. Bauml: Clarity on IO and TKI study data in 1L mNSCLC

Dr Joshua Bauml from the University of Pennsylvania in Philadelphia, Pennsylvania, discusses the role of IO and EGFR TKIs in the first-line treatment of patients with metastatic EGFR mutation-positive NSCLC. He concludes by looking at progression-free survival with TAGRISSO® (osimertinib) vs standard-of-care EGFR TKIs in the FLAURA study.
10 min 48sec.

Management of Adverse Reactions and Experience With TAGRISSO

Management of Adverse Reactions and Experience With TAGRISSO

Managing patient expectations regarding possible adverse reactions and how to manage them is a critical aspect of oncology nursing. In this presentation, Beth Sandy, MSN, CRNP, and Blanca Ledezma, MSN, NP, review the most common adverse reactions in the FLAURA study and discuss appropriate symptom management.
11min 45sec.

 

X


Important Safety Information Expand

  • There are no contraindications for TAGRISSO

  • Interstitial lung disease (ILD)/pneumonitis occurred in 3.9% of the 1142 TAGRISSO-treated patients; 0.4% of cases were fatal. Withhold TAGRISSO and promptly investigate for ILD in patients who present with worsening of respiratory symptoms which may be indicative of ILD (eg, dyspnea, cough and fever). Permanently discontinue TAGRISSO if ILD is confirmed

  • Heart rate-corrected QT (QTc) interval prolongation occurred in TAGRISSO-treated patients. Of the 1142 TAGRISSO-treated patients in clinical trials, 0.9% were found to have a QTc >500 msec, and 3.6% of patients had an increase from baseline QTc >60 msec. No QTc-related arrhythmias were reported. Conduct periodic monitoring with ECGs and electrolytes in patients with congenital long QTc syndrome, congestive heart failure, electrolyte abnormalities, or those who are taking medications known to prolong the QTc interval. Permanently discontinue TAGRISSO in patients who develop QTc interval prolongation with signs/symptoms of life-threatening arrhythmia

  • Cardiomyopathy occurred in 2.6% of the 1142 TAGRISSO-treated patients; 0.1% of cardiomyopathy cases were fatal. A decline in left ventricular ejection fraction (LVEF) ≥10% from baseline and to <50% LVEF occurred in 3.9% of 908 patients who had baseline and at least one follow-up LVEF assessment. Conduct cardiac monitoring, including assessment of LVEF at baseline and during treatment, in patients with cardiac risk factors. Assess LVEF in patients who develop relevant cardiac signs or symptoms during treatment. For symptomatic congestive heart failure, permanently discontinue TAGRISSO

  • Keratitis was reported in 0.7% of 1142 patients treated with TAGRISSO in clinical trials. Promptly refer patients with signs and symptoms suggestive of keratitis (such as eye inflammation, lacrimation, light sensitivity, blurred vision, eye pain and/or red eye) to an ophthalmologist

  • Postmarketing cases consistent with Stevens-Johnson syndrome (SJS) and erythema multiforme major (EMM) have been reported in patients receiving TAGRISSO. Withhold TAGRISSO if SJS or EMM is suspected and permanently discontinue if confirmed

  • Verify pregnancy status of females of reproductive potential prior to initiating TAGRISSO. Advise pregnant women of the potential risk to a fetus. Advise females of reproductive potential to use effective contraception during treatment with TAGRISSO and for 6 weeks after the final dose. Advise males with female partners of reproductive potential to use effective contraception for 4 months after the final dose

  • Most common adverse reactions (≥20%) were diarrhea, rash, dry skin, nail toxicity, stomatitis, fatigue and decreased appetite

Indications

  • TAGRISSO is indicated for the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 L858R mutations, as detected by an FDA-approved test

  • TAGRISSO is indicated for the treatment of patients with metastatic EGFR T790M mutation-positive NSCLC, as detected by an FDA-approved test, whose disease has progressed on or after EGFR tyrosine kinase inhibitor (TKI) therapy


Please see complete Prescribing Information including Patient Information.

You may report side effects related to AstraZeneca products by clicking here.

read more